2126 Stock Overview
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors.
JW (Cayman) Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$3.30|
|52 Week High||HK$17.18|
|52 Week Low||HK$3.20|
|1 Month Change||-48.03%|
|3 Month Change||-64.13%|
|1 Year Change||-79.71%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-85.00%|
Recent News & Updates
|2126||HK Biotechs||HK Market|
Return vs Industry: 2126 underperformed the Hong Kong Biotechs industry which returned -61.3% over the past year.
Return vs Market: 2126 underperformed the Hong Kong Market which returned -25% over the past year.
|2126 Average Weekly Movement||11.0%|
|Biotechs Industry Average Movement||8.4%|
|Market Average Movement||6.3%|
|10% most volatile stocks in HK Market||12.6%|
|10% least volatile stocks in HK Market||3.1%|
Stable Share Price: 2126 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: 2126's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.
JW (Cayman) Therapeutics Fundamentals Summary
|2126 fundamental statistics|
Is 2126 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2126 income statement (TTM)|
|Cost of Revenue||CN¥64.63m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.07|
|Net Profit Margin||-878.98%|
How did 2126 perform over the long term?See historical performance and comparison
Is 2126 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2126?
Other financial metrics that can be useful for relative valuation.
|What is 2126's n/a Ratio?|
Price to Sales Ratio vs Peers
How does 2126's PS Ratio compare to its peers?
|2126 PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
2142 HBM Holdings
1228 CANbridge Pharmaceuticals
6628 Transcenta Holding
2126 JW (Cayman) Therapeutics
Price-To-Sales vs Peers: 2126 is good value based on its Price-To-Sales Ratio (12.7x) compared to the peer average (25.9x).
Price to Earnings Ratio vs Industry
How does 2126's PE Ratio compare vs other companies in the HK Biotechs Industry?
Price-To-Sales vs Industry: 2126 is good value based on its Price-To-Sales Ratio (12.7x) compared to the Hong Kong Biotechs industry average (20x)
Price to Sales Ratio vs Fair Ratio
What is 2126's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||12.7x|
|Fair PS Ratio||6.9x|
Price-To-Sales vs Fair Ratio: 2126 is expensive based on its Price-To-Sales Ratio (12.7x) compared to the estimated Fair Price-To-Sales Ratio (6.9x).
Share Price vs Fair Value
What is the Fair Price of 2126 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2126's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2126's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is JW (Cayman) Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2126 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2126 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2126 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2126's revenue (48.7% per year) is forecast to grow faster than the Hong Kong market (9.7% per year).
High Growth Revenue: 2126's revenue (48.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2126 is forecast to be unprofitable in 3 years.
Discover growth companies
How has JW (Cayman) Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2126 is currently unprofitable.
Growing Profit Margin: 2126 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 2126 is unprofitable, and losses have increased over the past 5 years at a rate of 12.8% per year.
Accelerating Growth: Unable to compare 2126's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2126 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (10.2%).
Return on Equity
High ROE: 2126 has a negative Return on Equity (-32.7%), as it is currently unprofitable.
Discover strong past performing companies
How is JW (Cayman) Therapeutics's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 2126's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥165.3M).
Long Term Liabilities: 2126's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥127.7M).
Debt to Equity History and Analysis
Debt Level: 2126 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 2126's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2126 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 2126 has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 41.2% each year.
Discover healthy companies
What is JW (Cayman) Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2126's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2126's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2126's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2126's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 2126 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
James Li (58 yo)
Dr. Yiping Li, M.D., also known as James, has been a Partner of KPCB China Fund, which is an affiliate of TDF Capital China II, LP, since 2009. He serves as Co-founder and Executive Chairman at JW (Cayman)...
Experienced Management: 2126's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Experienced Board: 2126's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|17 Nov 21||SellHK$13,303,498||Cheng Liu||Individual||1,000,000||HK$13.30|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
JW (Cayman) Therapeutics Co. Ltd's employee growth, exchange listings and data sources
- Name: JW (Cayman) Therapeutics Co. Ltd
- Ticker: 2126
- Exchange: SEHK
- Founded: 2016
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$1.344b
- Shares outstanding: 411.03m
- Website: https://www.jwtherapeutics.com
Number of Employees
- JW (Cayman) Therapeutics Co. Ltd
- Building B
- 5th Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|2126||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Ordinary Shares||HK||HKD||Nov 2020|
|JWCT.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Nov 2020|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/26 00:00|
|End of Day Share Price||2022/09/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.